Weekly take: EU’s NGT plant patent ban is a ‘fatal signal’

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Weekly take: EU’s NGT plant patent ban is a ‘fatal signal’

fatal signal-comp.jpg

Banning patents on plants produced by new genomic techniques could damage innovation and jobs in Europe, says Jörg Thomaier, head of IP at Bayer

Biotechnology has been identified as one of the key technologies with a significant potential to boost Europe’s competitiveness whilst providing solutions that contribute to reaching the EU’s sustainability ambitions.

A new regulation for plants produced by certain new genomic techniques (NGT), such as targeted gene editing, would represent an important milestone in fostering and therewith creating a growing economy and more employment in the biotechnology sector of Europe.

It was therefore highly welcomed that on Wednesday, February 7, the European Parliament voted in favor of a new regulatory framework to regulate the release and use of NGT plants in argriculture.

However, at the same time, Members of the European Parliament (MEPs) amended the European Commission’s proposal to introduce a new full exclusion from patentability for all NGT plants (plants obtained by new genomics techniques such as targeted mutagenesis and cisgenesis) and further even for plants obtained by random mutagenesis techniques or cell fusion.

This caused quite some criticism.

Without adequate patent protection, companies in Europe will not be able to invest in NGTs, the pace of innovation will slow down, and the EU’s goal of fostering competitiveness with stronger biotechnology contributions will be put at risk.

For a successful introduction of NGTs, both adequate regulatory requirements and patent protection are crucial.

Patent and regulatory law fulfil different tasks.

The regulatory framework serves to protect health and the environment, whereas the patent system is designed to stimulate innovation and the economy.

New technologies such as gene editing and NGTs offer new opportunities. With these innovations, scientists can make very specific changes in a plant to develop new varieties with targeted desirable characteristics.

However, they require significant R&D investments to develop such varieties.

The ability to protect newly created traits with patents is an essential component to secure sustainable investments into R&D for the successful breeding of innovative crops that help farmers keep up productivity in times of climate change and help introduce more sustainable cropping systems.

Fatal signal

Patent bans are therefore a fatal signal.

In the European parliament, it was said that the ban may help to avoid new dependencies of farmers and breeders from patent holding companies. Patent bans are often misperceived to be a solution, but rather end up being detrimental to further innovation.

A patentability ban could result in less to no further developments specific to agricultural conditions in Europe as there would be no adequate compensation for the efforts.

Plant breeding is a highly regional business. For example, seeds produced in the mid-west of the US, might not be well-suited for Europe or Latin America.

Should there be no adequate patent protection, it is hard to see who would develop and work on specific regional solutions for Europe using these new techniques.

Plant variety protection alone falls too short. Patents are the only legally available tool to protect new traits.

The general research exemption and the breeders’ exemptions already implemented by many EU member states, and being part of the new unitary patent system enable free experimentation, breeding and development of new plants.

Together with an equitable and fair licensing policy, enabling the commercialisation of new plants patents does not block access but stimulates innovation.

Enabling the dissemination of innovation to many breeders, provides more choice and value-added solutions for farmers.

Patent protection secures a level playing field between competing companies, and fair licensing is prone to doing the same for small market players and larger cooperations.

Over the last year or so, several voluntary initiatives have been launched across the crop sector intending to facilitate access to patented materials.

In addition, under the EU's Biotech Directive, farmers are entitled to save seeds under the same conditions as for plant variety protection. Small farmers do not have to pay anything.

A solution should be reached that acknowledges the importance for small market participants to gain access to genetic material while respecting the importance of patent protection for trait innovators.

This would, in our view, be the only option to give NGT technology a chance to deliver on its promises in Europe for the benefit of all. We should first wait for publication of a much-needed fact-based study into NGTS that has been announced by the commission.

Excluding these technologies from patentability is surely not the solution.

more from across site and SHARED ros bottom lb

More from across our site

Deals between five more law firms and President Trump and an antitrust lawsuit against Amgen were also among the top talking points this week
US counsel explain how they win new cleantech IP business and how they’re navigating the industry’s challenges
Leaders at the IP firms, which have joined forces with backing from a PE investor, share their vision of building the number one pan-European IP practice
Firms will steer clients towards other ways of getting quicker examinations, but fear the ramifications of the USPTO’s decision
Melissa Haapala added that returning to client advocacy and the chance to work on patent litigation were reasons for returning to private practice
Michelle Clark, who has a generalist litigation background, plans to focus on IP disputes at Alston & Bird
Philips and Vivo have entered into a licensing agreement, putting an end to a five-year-old telecom SEP dispute in India
Stefan Müller discusses managing deadlines, the importance of reflection, and why IP is more than just a 'nice to have'
The three founders of the IP firm’s new US offering say they plan to offer a unique proposition in a market fixated by the billable hour
The opinion provides useful guidance when it comes to how courts might consider contributory infringement, DMCA claims, and other issues in AI copyright cases
Gift this article